NCT04985058 Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
| NCT ID | NCT04985058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hellenic Cooperative Oncology Group |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 108 participants |
| Start Date | 2021-10-06 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 108 participants in total. It began in 2021-10-06 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed HR-positive, HER2-negative breast cancer * Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology * 18 years or older * Any menopausal status * Treatment with abemaciclib in combination with endocrine therapy * Any endocrine therapy * At least two months of treatment with abemaciclib
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04985058 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04985058 currently recruiting?
Yes, NCT04985058 is actively recruiting participants. Contact the research team at FOUNTZILA@ONCOGENOME.GR for enrollment information.
Where is the NCT04985058 trial being conducted?
This trial is being conducted at Athens, Greece.
Who is sponsoring the NCT04985058 clinical trial?
NCT04985058 is sponsored by Hellenic Cooperative Oncology Group. The trial plans to enroll 108 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.